Terms: = Head and neck cancer AND NRAS, N-ras, 4893, ENSG00000213281, P01111, NRAS1 AND Clinical Outcome
12 results:
1. Prognostic biomarkers for survival in mucosal melanoma.
Thierauf JC; Kaluziak ST; Codd E; Dybel SN; Jobbagy S; Purohit R; Farahani AA; Dedeilia A; Naranbhai V; Hoang MP; Fisch AS; Ritterhouse L; Boland GM; Lennerz JK; Iafrate AJ
Pigment Cell Melanoma Res; 2023 Sep; 36(5):378-387. PubMed ID: 37390098
[TBL] [Abstract] [Full Text] [Related]
2. Molecular characterisation and clinical correlation of papillary thyroid microcarcinoma.
Samà MT; Grosso E; Mele C; Laurora S; Monzeglio O; Marzullo P; Boldorini R; Aluffi Valletti P; Aimaretti G; Scatolini M; Pagano L
Endocrine; 2021 Jan; 71(1):149-157. PubMed ID: 32621051
[TBL] [Abstract] [Full Text] [Related]
3. Next-Generation Sequencing Identifies Gene Mutations That Are Predictive of Malignancy in Residual Needle Rinses Collected From Fine-Needle Aspirations of Thyroid Nodules.
Fuller MY; Mody D; Hull A; Pepper K; Hendrickson H; Olsen R
Arch Pathol Lab Med; 2018 Feb; 142(2):178-183. PubMed ID: 28537807
[TBL] [Abstract] [Full Text] [Related]
4. The Role of SATB2 as a Diagnostic Marker of Sinonasal Intestinal-type Adenocarcinoma.
Skalova A; Sar A; Laco J; Metelkova A; Miesbauerova M; Steiner P; Švajdler M; Michal M
Appl Immunohistochem Mol Morphol; 2018 Feb; 26(2):140-146. PubMed ID: 27258560
[TBL] [Abstract] [Full Text] [Related]
5. Genomic Profiling of Thyroid cancer Reveals a Role for Thyroglobulin in Metastasis.
Siraj AK; Masoodi T; Bu R; Beg S; Al-Sobhi SS; Al-Dayel F; Al-Dawish M; Alkuraya FS; Al-Kuraya KS
Am J Hum Genet; 2016 Jun; 98(6):1170-1180. PubMed ID: 27236916
[TBL] [Abstract] [Full Text] [Related]
6. Diffuse sclerosing variant of papillary thyroid carcinoma: major genetic alterations and prognostic implications.
Joung JY; Kim TH; Jeong DJ; Park SM; Cho YY; Jang HW; Jung YY; Oh YL; Yim HS; Kim YL; Chung JH; Ki CS; Kim SW
Histopathology; 2016 Jul; 69(1):45-53. PubMed ID: 26568156
[TBL] [Abstract] [Full Text] [Related]
7. TERT promoter mutations in sinonasal malignant melanoma: a study of 49 cases.
Jangard M; Zebary A; Ragnarsson-Olding B; Hansson J
Melanoma Res; 2015 Jun; 25(3):185-8. PubMed ID: 25746036
[TBL] [Abstract] [Full Text] [Related]
8. Prognostic biomarkers in phase II trial of cetuximab-containing induction and chemoradiation in resectable HNSCC: Eastern cooperative oncology group E2303.
Psyrri A; Lee JW; Pectasides E; Vassilakopoulou M; Kosmidis EK; Burtness BA; Rimm DL; Wanebo HJ; Forastiere AA
Clin Cancer Res; 2014 Jun; 20(11):3023-32. PubMed ID: 24700741
[TBL] [Abstract] [Full Text] [Related]
9. Pre-operative role of BRAF in the guidance of the surgical approach and prognosis of differentiated thyroid carcinoma.
Danilovic DL; Lima EU; Domingues RB; Brandão LG; Hoff AO; Marui S
Eur J Endocrinol; 2014 Apr; 170(4):619-25. PubMed ID: 24468978
[TBL] [Abstract] [Full Text] [Related]
10. Cribriform-morular variant of papillary thyroid carcinoma displaying poorly differentiated features.
Nakazawa T; Celestino R; Machado JC; Cameselle-Teijeiro JM; Vinagre J; Eloy C; Benserai F; Lameche S; Soares P; Sobrinho-Simões M
Int J Surg Pathol; 2013 Aug; 21(4):379-89. PubMed ID: 23349472
[TBL] [Abstract] [Full Text] [Related]
11. Epidermal growth factor receptor, phosphatidylinositol-3-kinase catalytic subunit/PTEN, and KRAS/nras/BRAF in primary resected esophageal adenocarcinomas: loss of PTEN is associated with worse clinical outcome.
Bettstetter M; Berezowska S; Keller G; Walch A; Feuchtinger A; Slotta-Huspenina J; Feith M; Drecoll E; Höfler H; Langer R
Hum Pathol; 2013 May; 44(5):829-36. PubMed ID: 23158210
[TBL] [Abstract] [Full Text] [Related]
12. Aneuploidy and high S-phase as biomarkers of poor clinical outcome in poorly differentiated and anaplastic thyroid carcinoma.
Pinto AE; Silva G; Banito A; Leite V; Soares J
Oncol Rep; 2008 Oct; 20(4):913-9. PubMed ID: 18813835
[TBL] [Abstract] [Full Text] [Related]
